AstraZeneca and Innate Pharma enter into partnership for the development of CD39 mAbs
23 October 2018
Meet us at the 2018 Bio Europe meeting in Copenhagen
17 November 2018Press Release
Lyon, October 8, 2018
Interleukin-17 patent granted in Europe
Lyon, France, October 8, 2018 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced the grant of patent EP2569335 by the European Patent Office. This patent covers IL-17A neutralizing antibodies for use as a therapeutic tool to increase the response to other chemotherapeutic agents. “The delivery of this European Patent is another important milestone for OREGA Biotech; it is the fifth issued patent related to our IL‑17 programs”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech. “Intellectual property is a key asset in OREGA’s target discovery programs. Our capacity to obtain broad claims covering novel cancer targets offers a valuable competitive advantage.”
